Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-125b
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Prognosis/Treatment
Upstream regulatory factors
Not available
Downstream target
SMYD2
Cancer name
Renal Cell Carcinoma
Cancer site
Kidney
Treatment type
Chemotherapy
Drug
5-Fluorouracil/Cisplatin/Docetaxel/Doxorubicin/Sunitinib
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Down
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
SMYD2 and miR-125b inhibition acted synergistically with anticancer drugs via P-gP suppression in vitro and in vivo.
Tissue resource
renal cell carcinoma tissues and matched adjacent normal tissues
renal cell carcinoma cell lines HK-2
human embryonic kidney cell lines HEK-293T
Experiment
qRT-PCR
Institute
the Wuhan Tongji Hospital
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.